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httpsWHAT THIS PAPER ADDS
Lymphoedema management currently relies on standard conservative treatments that include manual lymphatic
drainage followed by compression strategies to contain the swelling. As lymphoedema is a chronic disease, it
requires lifelong management with onerous consequences for patients’ quality of life. The results presented here
pave the way for an innovative treatment option that proposes to substitute the impaired lymphatic system with
an implanted drainage device that would re-establish physiological drainage.Objective: Despite recent advances in pharmacological research and microsurgery, lymphoedema remains an
incurable disease that deeply affects quality of life. There is an urgent need for innovative approaches to
restore continuous lymph ﬂow in affected tissues. To this end, the efﬁcacy of a subcutaneously implanted
draining device in reducing lymphoedema volume in a rat hindlimb lymphoedema model was tested.
Methods: A rat model of chronic lymphoedema was developed by surgical removal of popliteal and inguinal lymph
nodes, followed by irradiation. The model was characterised by monitoring limb volume via tape measure, skin
water content via dielectric constant measurement, and lymphatic drainage via lymphoﬂuoroscopy. After
lymphoedema establishment in 16 Wistar rats, a device made of fenestrated tubing equipped with a
miniaturised pumping system, was implanted subcutaneously in the affected limb to restore continuous
recirculation of interstitial ﬂuid.
Results: Lymphoﬂuoroscopy imaging showed impaired lymphatic drainage following lymphadenectomy and
irradiation. Affected limb volume and skin water content increased signiﬁcantly compared with the untreated
limb, with a median (interquartile range) of 3.85 (0.38) cm3 versus 3.03 (0.43) cm3 for volume (n ¼ 16,
p ¼ .001) and 26.6 (9.1) versus 16.6 (3.7) cm3 for skin dielectric constant (n ¼ 16, p ¼ .001). Treatment of
lymphoedema with the implanted drainage device showed that 5 weeks post-implant excess volume was
signiﬁcantly reduced by 51  18% compared with the pre-implant situation (n ¼ 9 sham group, n ¼ 7 pump
group).
Conclusion: Lymphoedema volume in the rat model was signiﬁcantly reduced by restoring continuous drainage
of excess ﬂuid using a novel subcutaneously implanted device, opening the way to the development of an
artiﬁcial lymphatic vessel.Keywords: Implantable pump, Lymphoedema, Subcutaneous drainage
Article history: Received 15 February 2018, Accepted 22 April 2018, Available online 25 May 2019
 2018 The Authors. Published by Elsevier B.V. on behalf of European Society for Vascular Surgery. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Triacca and M. Pisano contributed equally to this work.
responding author. Angiology Division/CHUV, Chemin de Mont Pai-
, Lausanne, CH 1011, Switzerland.
il address: lucia.mazzolai@chuv.ch (Lucia Mazzolai).
-5884/ 2018 The Authors. Published by Elsevier B.V. on behalf of Eu-
Society for Vascular Surgery. This is an open access article under the CC
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
://doi.org/10.1016/j.ejvs.2018.04.014INTRODUCTION
Secondary lymphoedema (LE) is a frequent chronic, yet
underrecognised, disease characterised by the accumula-
tion of interstitial ﬂuid and macromolecules leading to tis-
sue swelling. Cancer and cancer related interventions (i.e.,
surgery, radiotherapy) are frequent causes of LE occurring
both in the upper and lower limbs.1e4 Currently, no curative
treatment exists for LE, and management of patients is
860 Valentina Triacca et al.based mainly on chronic symptomatic therapy consisting of
complete decongestive therapy, a combination of skin care,
manual lymphatic drainage (MLD), decongestive exercises,
and compression strategies aimed at reducing and then
containing the swelling of the affected limb.5 Alternative
treatments for LE are reconstructive and debulking surgical
techniques.
Reconstructive surgery aims to restore lymphatic function
with newly created lymphoevenous or lymphoelymphatic
bypass, with lymphoelymphatic venous segmental recon-
struction, or by vascularised lymph node transfer.6e10 One
interesting technique was recently developed, consisting of
the subcutaneous implantation of silicone tubes with lateral
access holes that create a draining route bypassing the region
with non-functional lymphatic vessels.11,12 Compression
therapy is needed to create the pressure necessary to drive
the interstitial ﬂuid into the silicone tubes.
Despite advancements in lymphatic surgery, complete
decongestive therapy remains the standard of care,
involving lifelong treatment that signiﬁcantly impacts on
quality of life.13 Patients not only need to attend frequent
physiotherapy sessions, but they also need to wear heavy
and cumbersome compression garments between sessions.
The lives of patients with LE are affected by the continuous
fear of skin infection (erysipelas), by the fact that LE rep-
resents a constant reminder of their treated cancer, and by
a series of limitations at the social and personal level.14,15
There is therefore an urgent and great need to develop
innovative treatment strategies to improve the quality of
life of patients with LE.
To this end, animal models closely reproducing the
pathophysiology and progression of the disease are
extremely important. Even though several animal models
have been described in the past, there is still a lack of well
characterised and reproducible models suitable to test
among other treatments, surgical procedures. Models of LE
in rabbits, dogs, and sheep have several limitations,
including transient effect, high mortality, and no volume
increase.16,17 Volume increase was reported in porcine
models, but the LE observed was only acute.18 Currently the
most reliable animal models of LE are developed in rodents,
both in the hindlimb and in the tail. The tail model is useful
to study the pathophysiology of the disease, and to test
drug formulations and regenerative approaches, but it is
unsuitable to test surgical procedures. The hindlimb model
in rodents is the only model to show stable LE induction
after lymphadenectomy and irradiation.19e21
Based on these observations, the ﬁrst aim of this study
was to generate and verify the chronicity of the rat hindlimb
LE model, based on the surgical removal of popliteal and
inguinal lymph nodes, followed by irradiation of the inguinal
area. The second aim was to test a novel technique to treat
LE, based on active internal drainage of the excessive
interstitial ﬂuid. Using the rat hindlimb model, the feasibility
of draining excess ﬂuids and reducing LE using a unique,subcutaneously implanted peristaltic pump connected to a
drainage catheter placed in the oedematous tissue has been
investigated for the ﬁrst time.MATERIALS AND METHODS
Rat hindlimb lymphoedema model
Female Wistar rats (250e300 g) were purchased from
Charles River Laboratories (Saint-Germain-sur-l’Arbresle,
France). Animals were allowed to acclimatise to their new
environment for 1 week before the start of the experi-
mental procedure. Animals were housed in conventional
facilities and handled according to institutional regula-
tions after ethical approval from the Ofﬁce Vétérinaire
Cantonale Vaud, Switzerland (authorisation VD2911). Ex-
periments were conducted in accordance with Directive
2010/63/EU of the European Parliament. LE was induced
in the left hindlimb by removal of popliteal and inguinal
lymph nodes, followed by irradiation. The right hindlimb
was left untreated and used as an internal control. Prior
to surgery, rats received buprenorphine analgesia (Tem-
gesic 0.05 mg/kg, subcutaneously). Anaesthesia was
induced with isoﬂurane (4% for induction and 1e1.5%
throughout the procedure). Lymphatic vessels were
visualised by intradermal injection of 10 mL 10% Evans
Blue (SigmaeAldrich, Buchs, Switzerland) solution into the
dorsum of the paw. Through a 2 cm skin incision, the
groin fat pad was completely resected to remove inguinal
lymph nodes. The popliteal lymph node was identiﬁed by
Evans blue accumulation and excised. Internal sutures
were used to close the scar. Healing was allowed over 1
week, during which rats received analgesia (buprenor-
phine for the ﬁrst 2 days followed by 2 g/L paracetamol in
drinking water) and during which they were monitored
daily. One to two weeks after surgery, rats were posi-
tioned using a ﬂuoroscan (Fig. S1; see Supplementary
Material) and the inguinal area was irradiated under
isoﬂurane anaesthesia with 22.7 Gy at 225 keV and 13 mA
(X-RAD 225cx; Precision X-Ray, North Branford, CT, USA)
administered with two opposing beams, antero-posterior
and postero-anterior. The dose was prescribed at 10 mm
depth and administered with a 40  40 mm square
collimator. Irradiated skin was treated topically with Bia-
ﬁne emulsion for 3 days following irradiation. Bodyweight
was monitored throughout the entire experiment. At the
end of the experiment animals were euthanised with an
intraperitoneal injection of at least 200 mg/kg sodium
pentobarbital.
Monitoring of lymphoedema
Hindlimb oedema (volume) was calculated by truncated
cone approximation. Limb circumference was measured at
ﬁve different levels, 1e3 cm between the heel and the
knee. The volume of the affected hindlimb was compared
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constant, an indirect measure of water content, was
measured using a moisture meter (MoistureMeterD [small
probe]; Delﬁn Technologies, Kuopio, Finland) at three
different anatomical locations: the dorsum of the paw, and
the dorsal and ventral hindlimb.Lymphoﬂuoroscopy
At the end of the experimental period lymphoﬂuoroscopy was
performed on both the affected and unaffected hindlimb.
Cardiogreen dye (SigmaeAldrich) was diluted at 1 mg/mL in
sterile water, and 5 mL of this solution were injected intra-
dermally in the dorsum of the paw in anaesthetised rats.
Physiological lymphatic drainage of the injected dye was
monitored with a PDE Near Infrared Fluorescence Imager
(Hamamatsu Photonics, Shizuoka, Japan).The anatomical level
reached by the dye wasmarked on the skin every 5min, for up
to 15 min. Lymphatic drainage speed was calculated by
measuring the distance between the injection spot and the
skin marks divided by the time interval. MLD, using ﬁll-in and
ﬂush maneouvres,22 was performed in the LE limb 15 min
following dye injection.Outle
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Figure 1. Subcutaneous implantation of a drainage pump connected to
Schematic drawing of the inlet tube, the pump, and the outlet tube in
Close up of the lymphoedematous area showing the lateral access hole
aspiration mode (pump [Antlia SA, Lausanne, Switzerland], diameter ¼Drainage device implantation and activation
Eight to ten weeks after irradiation of the hindlimb a
drug delivery pump (Ithetis pump; Antlia SA, Lausanne,
Switzerland), modiﬁed to work in aspiration mode, was
implanted in a subcutaneous pocket created in the back
of the rat, with the inlet tubing positioned in the sub-
cutaneous tissue in the left hindlimb (lymphoedematous
tissue), and the outlet tubing placed in the subcutane-
ous space close to the pump (Fig. 1). Rats were
anaesthetised, and a 2e3 cm incision was made in the
back skin. A subcutaneous pocket was created with
surgical scissors and a tunnel between the cut in the
back and the hindlimb was created with a Kel-F hub
12 G needle, 152 mm long (Hamilton Bonaduz AG,
Bonaduz, Switzerland). The inlet tubing was inserted in
the inner lumen of the needle and the needle was
removed. The pump and outlet tubing were placed in a
subcutaneous pocket created in the rat’s back. The
wound was closed with resorbable sutures and the
pump was activated in order to drain 3 mL/h. Rats were
monitored for 5 weeks after implantation of the device.
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s in the inlet tube. (D) Drug delivery device modiﬁed to work in
21 mm, thickness ¼ 7 mm).
862 Valentina Triacca et al.and the lymphoedematous limb was recorded (interlimb
difference). Values were normalised to the interlimb
difference right before implant. Sham surgery was per-
formed on a second group of rats.Statistical analysis
All data shown are expressed as median (interquartile
range), unless stated differently in the result section and in
the ﬁgure legends. Comparisons between the left hindlimb
and the right hindlimb, used as internal control, were done
by two tailed Wilcoxon signed rank test. Comparison be-
tween sham surgery and pump group was done by two
tailed ManneWhitney test. p Values < .05 were considered
statistically signiﬁcant.3
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Figure 2. Lymphadenectomy followed by irradiation resu
measure limb circumference and calculate limb volume by
surgery and irradiation in the left limb (LE limb) and in
***p < .001 (n ¼ 16). (C) Representative pictures of
LE ¼ lymphoedema; Rt ¼ time of irradiation.RESULTS
Efﬁcacy of lymphadenectomy/irradiation
Lymph node removal and irradiation caused the formation
of a stable oedema, as quantiﬁed by a statistically signiﬁ-
cant increase in hindlimb volume compared with the
contralateral side (3.85 [0.38] cm3 vs. 3.03 [0.43] cm3 eight
weeks after irradiation [p ¼ .001, n ¼ 16]; Fig. 2A and B).
The lymphoedematous limb was characterised by non-
pitting oedema corresponding to the ankle joint and by
skin folds similar to the ones observed in patients with LE
(Fig. 2C).
Eight weeks after irradiation, the skin dielectric constant
was signiﬁcantly elevated in the oedematous hindlimb, on
both the ventral and dorsal side (ventral side: 22.7 [9.7] LE5.0
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Figure 3. The skin dielectric constant is higher in the lymphoedematous limb. (A) Dielectric constant mea-
surement points. (B) Skin dielectric constant in the ventral hindlimb in the left limb (LE) and in the control
limb. (C) Skin dielectric constant in the dorsal hindlimb in the LE and control limb. (D) Skin dielectric
constant in the dorsum of the paw in the LE and control limb. **p < .01, ***p < .001 (n ¼ 16).
LE ¼ lymphoedema.
Experimential Drainage Device for Lymphoedema Treatment 863vs. 15.2 [2.9] control [p ¼ .001]; dorsal side: 26.6 [9.1] LE vs.
16.5 [3.7] control [p ¼ .002]; Fig. 3AeC) but not on the
dorsum of the paw (18.9 [3.8] LE vs. 18.0 [2.3] control
[p ¼ .093]; Fig. 3D).
Lymphatic ﬂow
Lymphoﬂuoroscopy was performed to assess lymphatic
drainage. Lymphatic vessels were clearly identiﬁed in
the healthy limb 10 min after injection of the ﬂuores-
cent tracer. Conversely, in the lymphoedematous limb
the injected dye mainly diffused, and no clear routes of
drainage were identiﬁed (Fig. 4A). Drainage speed was
signiﬁcantly reduced in the oedematous limb compared
with the untreated control (Fig. 4B). To conﬁrm impaired
drainage capacity in the LE limb, imaging of the injec-
tion site was performed 24 h after injection, showing
almost complete drainage of the dye in the healthy limb
and stagnation of ﬂuid in the LE limb (Fig. 4C). In one
case the formation of collateral drainage routes
following MLD was observed, connecting the left limb
with the right inguinal lymph node (Fig. 4D). These
collateral routes were, however, insufﬁcient to sustainproper lymphatic ﬂow as they could only be visualised
following MLD.
Continuous artiﬁcial drainage results in hindlimb volume
reduction
Five weeks following device implant the interlimb volume
difference was reduced by 51  18% (Fig. 5A
[p ¼ .009 at week 5]), corresponding to a mean  SD
interlimb volume reduction of 0.60 cm3  0.70 in the
pump group, versus a mean  SD interlimb volume in-
crease of þ0.41 cm3  0.57 in the sham group (Fig. S2;
see Supplementary Material). In four cases the battery
lasted 2 weeks after implant, whereas in three cases the
battery lasted for 5 weeks. In one case, 1 week after im-
plantation, kinking of the inlet tubing was observed. At
week 3 after implant the rat underwent surgery to read-
just the tubing position. During the kinking period, while
drainage was impaired, a 97% volume increase was
observed versus the volume one week post-implant.
Following repositioning and re-establishment of correct
pump functioning, 2 weeks later, a 53% excess volume
reduction was observed (Fig. 5B). No signiﬁcant
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Figure 4. Lymphatic ﬂow is impaired after lymphadenectomy and surgery. (A) Lymphoﬂuoroscopy snapshot
10 min after intradermal injection of Cardiogreen in the paw in the control and in the lymphoedematous
(LE) limb. (B) Boxplot with min to max whiskers of drainage speed in the control and LE limb. *p < .05
(n ¼ 9). (C) Lymphoﬂuoroscopy snapshots 24 h after initial injection. (D) Visualisation of collateral
drainage route from the LE limb to the right inguinal lymph node, after manual lymphatic drainage (MLD)
in the left limb. LE ¼ lymphoedema.
864 Valentina Triacca et al.differences in dielectric constant ratio (LE limb/healthy
limb) between treated (device) and sham group were
observed (Fig. 5C).
DISCUSSION
These results show for the ﬁrst time, the feasibility of
signiﬁcant LE volume reduction via a subcutaneously
implanted device composed of fenestrated tubing equip-
ped with a miniaturised pump. To the best of the authors’
knowledge, this is the ﬁrst time this approach has been
investigated. Results were obtained in a chronic rat hin-
dlimb LE model. The model used follows those described
previously, adding further knowledge to the characteri-
sation of LE.19e21 Adapted to the rat model was the
measurement of the dielectric constant (indirect measure
of water content), which showed a signiﬁcant increase in
the LE limb. Along the same lines, lymphoﬂuoroscopy
imaging was adapted to the rat to visualise and assess
impaired lymphatic drainage.
The rat hindlimb model closely mimics the pathophysio-
logical and anatomical aspects observed in chronic LEpatients, outperforming the rabbit, canine, sheep, and
porcine models that either require highly specialised sur-
gical skills, have low reliability, or result only in acute
lymphatic damage.18,23e25 Minor limitations remain, mainly
linked to the size of the animal: lymph ﬂow rates are
different between rats and human. Moreover, the model
requires irradiation to trigger LE formation, with conse-
quent temporary skin injury and inﬂammation, and the risk
of radiation recall effect as described in patients.26 Never-
theless, despite these limitations, the rat LE hindlimb model
proved to be a useful and simple tool to test the feasibility
of an innovative approach to LE treatment. It has been
shown that continuous drainage of excess ﬂuids from the
oedematous limb results in signiﬁcant LE volume reduction
compared with the sham-operated animals. Moreover, it
was noticed that interruption of artiﬁcial drainage, even for
a brief time, is associated with regaining limb volume. The
excess volume signiﬁcantly decreased following device
reactivation, strongly suggesting a direct link between
artiﬁcial drainage and limb volume. Thus, this study shows
for the ﬁrst time the feasibility of treating chronic LE with an
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Figure 5. Lymphoedema volume is reduced by draining excess ﬂuid with an implanted pump. (A) Interlimb
volume change in rats implantedwith the pump and in the sham surgery control group. (B) Representative graph of
interlimb volume change in a case where kinking of the inlet tubingwas observed betweenweek 1 andweek 3 after
implantation. (C) Ratio of skin dielectric constant in the lymphoedema limb vs. control limb over time, for both the
sham and the pump groups. Data presented asmean SEM (standard error of themean). *p< .05, **p< .01, n¼ 9,
sham; n ¼ 7, pump (n ¼ 3 week 3e5).
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to an active pump.
The internal drainage was performed over a time-
frame suitable for observing the dynamics of volume
changes in the rat limb, compatible with the battery life
of the implantable pump. The pump used for the study
was used to obtain proof of concept, and the battery
performance observed was not optimal. For clinical
translatability of the current approach, a system to
ensure proper power supply throughout the lifetime of
the device would need to be designed. One approach
could be to ﬁnd a technological solution to completely
avoid battery implantation, for example by placing the
battery in a wearable device that is magnetically
coupled with the implantable pump. No differences
were found in the skin dielectric constant after pump
activation. This observation could be explained by the
fact that the moisture meter probe used for the study
(probe S) is designed to measure the dielectric constant
of the dermis, whereas the tubing connected to thepump is placed in the subcutaneous space. The limb
volume is affected by the subcutaneous drainage, but
the superﬁcial dermis water content is not.
These ﬁndings are in line with previous reports that
have proposed the use of silicone catheters implanted
subcutaneously for the treatment of LE: accumulated
interstitial ﬂuid was forced into subcutaneously implanted
hollow tubes by mean of external compression with
intermittent pneumatic compression pumps.11,12 Inter-
estingly, results showed reduction of limb circumference,
enhanced drainage, no cellular inﬁltrates, and no forma-
tion of ﬁbrotic tissue around the tubes, both in upper and
lower limb LE. Nevertheless, patients still needed to use
external compression therapy on a regular basis. Of great
interest, the advantage with the system proposed here
would be the elimination of the need for external
compression: the internal drainage is driven by the
implanted pump.
Compared with existing surgical techniques for the
treatment of LE, the approach proposed here presents
866 Valentina Triacca et al.several advantages. Firstly, the device could be implan-
ted by any surgeon, without the need for the highly
specialised skills and the expensive equipment required
for microsurgery. Secondly, the surgery would not be
limited to patients with functional lymphatics,27 but it
could potentially be extended to LE cases where lym-
phatics are more severely affected. The drainage cath-
eter would work as an artiﬁcial vessel, substituting the
role of the malfunctioning or completely non-functional
lymphatics.
In conclusion, the data presented here validate the rat
hindlimb model as an excellent model of chronic LE. Of
great importance, for the ﬁrst time the therapeutic efﬁcacy
of the use of an implanted system to reduce LE volume by
continuously draining excess ﬂuids from the oedematous
area is provided, opening the way to further clinical
investigation.
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